Ratings by Goldman Sachs (Matt Dellatorre)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 10/16/2026 | Zoetis Inc. | ZTS | New Coverage | Neutral (N/A) |
75.29 (79.62) |
5.75% | Details | |
| 10/16/2026 | Elanco Animal Health | ELAN | New Coverage | Buy (N/A) |
22.55 (22.55) |
0% | Details | |
| 10/16/2026 | IDEXX Laboratories | IDXX | New Coverage | Buy (N/A) |
529.01 (553.48) |
4.63% | Details | |
| 2/9/2026 | Teva Pharma | TEVA | Maintain | Neutral (N/A) |
|
Details | ||
| 9/23/2025 | Teva Pharma | TEVA | Maintain | Buy (N/A) |
|
Details | ||
| 7/18/2025 | Viatris | VTRS | Maintain | Neutral (N/A) |
|
Details | ||
| 6/30/2025 | Viatris | VTRS | Maintain | Neutral (N/A) |
|
Details | ||
| 6/6/2025 | Viatris | VTRS | New Coverage | Neutral (Neutral) |
8.59 (18.45) |
114.78% | Details | |
| 6/6/2025 | Amneal Pharmaceuticals | AMRX | New Coverage | Neutral (N/A) |
7.21 (20.20) |
180.17% | Details | |
| 6/6/2025 | Teva Pharma | TEVA | New Coverage | Buy (N/A) |
17.52 (40.62) |
131.85% | Details |
